Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Is it time to bail out of easyJet plc and buy GlaxoSmithKline plc instead?

A warning shot from easyJet plc (LON: EZJ) diverts attention to stable enterprises such as GlaxoSmithKline plc (LON: GSK)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The main takeaway I get from today’s half-year report from airline operator easyJet (LSE: EZJ) is that net cash from operations is down 40% compared to the equivalent period last year and the firm made an earnings-per-share loss of 5.1p, which compares to a profit of 1.3p per share last year.

No wonder, then, at 1,500p, the shares are down around 14% since the beginning of 2016. Whichever way we dress it up, this isn’t a good result for easyJet and the firm’s shareholders.

Precarious profits

The outcome here demonstrates what a precarious juggling act it is to keep an airline profitable and growing. During the period, easyJet faced pressure on its business from justifiably skittish customers due to travel strikes and terror attacks on European capitals.

That’s the thing with an airline: we never know when a natural disaster such as an Icelandic volcano or man-made disasters such as war, conflict, strike, terrorism or commodity speculation will shoot down the firm’s profitability. But it gets worse than that. Airlines are also at the mercy of macroeconomic events making airline businesses and their shares among the most cyclical on the stock market.

That cyclicality has implications about how the market is likely to value businesses such as easyJet. The more mature a macro-cycle becomes, the lower I would expect easyJet’s valuation to be as the market tries to anticipate the next cyclical down-leg by discounting high earnings in the boom times.

Consumer demand strong

Right now, easyJet trades on a forward price-to-earnings (P/E) ratio of nine for the year to September 2017 and sports a twice-covered 4.7% dividend yield. I wouldn’t expect a higher valuation than that, so any further share price progress probably needs to come from business growth rather than from a valuation rerating.

Carolyn McCall, easyJet’s chief executive says: easyJet has delivered a robust financial performance during the half year despite the well-publicised external events. Underlying consumer demand has been strong with UK beach traffic providing a healthy start to the half and easyJet’s biggest-ever ski season helping to deliver increased passenger numbers and higher revenue during H1.

Okay. But it’s precisely when things are going at their best that we should expect a cyclical top, often followed by a descent into the next cyclical bottom. Nobody knows when the top will arrive, but I’m taking these first-half losses as a warning shot and now I’m avoiding easyJet shares.

A more robust business model

Pharmaceutical giant GlaxoSmithKline (LSE: GSK) enjoys a more robust business model than easyJet’s. The stable nature of demand for medicines makes GlaxoSmithKline’s operation far less cyclical and keeps the cash taps flowing as consumers repeat purchase drugs.

Sure, the pharmaceutical industry had its challenges over patent expiry issues as once high-earning formulations lost exclusivity in the market and the firm saw a flood of generic competition erode profits. However, the company is moving on from that and hopes a new generation of blockbusters will return the firm to enduring growth.

City analysts following the firm expect earnings to grow 16% this year and 4% during 2014. At today’s 1,475p share price GlaxoSmithKline trades on a forward P/E rating of just over 16 for 2017 and yields a dividend of 5.4% covered just over once by forward earnings. That’s a fair valuation for a defensive business with reasonable forward growth prospects.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 FTSE 100 predictions for 2026

2025 has been a blockbuster year for the FTSE 100. Here’s what Edward Sheldon thinks will happen with the stock…

Read more »

Young woman holding up three fingers
Investing Articles

Want to start investing in 2026? 3 things to get ready now!

Before someone is ready to start investing in the stock market, our writer reckons it could well be worth them…

Read more »

Investing Articles

Can the stock market continue its strong performance into 2026?

Will the stock market power ahead next year -- or could its recent strong run come crashing down? Christopher Ruane…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

Here’s how someone could invest £20k in an ISA to target a 7% dividend yield in 2026

Is 7% a realistic target dividend yield for a Stocks and Shares ISA? Christopher Ruane reckons that it could be.…

Read more »

A quiet morning and an empty Victoria Street in Edinburgh's historic Old Town.
Investing Articles

How little is £1k invested in Greggs shares in January worth now?

Just how much value have Greggs shares lost this year -- and why has our writer been putting his money…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

This cheap FTSE 100 stock outperformed Barclays, IAG, and Games Workshop shares in 2025 but no one’s talking about it

This FTSE stock has delivered fantastic gains in 2025, outperforming a lot of more popular shares. Yet going into 2026,…

Read more »

Close-up of British bank notes
Investing Articles

100 Lloyds shares cost £55 in January. Here’s what they’re worth now!

How well have Lloyds shares done in 2025? Very well is the answer, as our writer explains. But they still…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing Articles

How much do you need in an ISA to target £2,000 a month of passive income

Our writer explores a passive income strategy that involves the most boring FTSE 100 share. But when it comes to…

Read more »